Your browser doesn't support javascript.
loading
STAMP2 increases oxidative stress and is critical for prostate cancer.
Jin, Yang; Wang, Ling; Qu, Su; Sheng, Xia; Kristian, Alexandr; Mælandsmo, Gunhild M; Pällmann, Nora; Yuca, Erkan; Tekedereli, Ibrahim; Gorgulu, Kivanc; Alpay, Neslihan; Sood, Anil; Lopez-Berestein, Gabriel; Fazli, Ladan; Rennie, Paul; Risberg, Bjørn; Wæhre, Håkon; Danielsen, Håvard E; Ozpolat, Bulent; Saatcioglu, Fahri.
Afiliación
  • Jin Y; Department of Biosciences, University of Oslo, Oslo, Norway Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Wang L; Department of Biosciences, University of Oslo, Oslo, Norway.
  • Qu S; Department of Biosciences, University of Oslo, Oslo, Norway.
  • Sheng X; Department of Biosciences, University of Oslo, Oslo, Norway Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Kristian A; Department of Tumor Biology, Oslo University Hospital, Oslo, Norway.
  • Mælandsmo GM; Department of Tumor Biology, Oslo University Hospital, Oslo, Norway.
  • Pällmann N; Department of Biosciences, University of Oslo, Oslo, Norway.
  • Yuca E; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Tekedereli I; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Gorgulu K; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Alpay N; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Sood A; Gynecological Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • Lopez-Berestein G; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Fazli L; The Vancouver Prostate Centre, Vancouver, BC, Canada.
  • Rennie P; The Vancouver Prostate Centre, Vancouver, BC, Canada.
  • Risberg B; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway Division of Pathology, Oslo University Hospital, Oslo, Norway Division of Surgery, Oslo University Hospital, Oslo, Norway.
  • Wæhre H; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway Division of Pathology, Oslo University Hospital, Oslo, Norway Division of Surgery, Oslo University Hospital, Oslo, Norway Center for Cancer Biomedicine, University of Oslo, Oslo, Norway.
  • Danielsen HE; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway Center for Cancer Biomedicine, University of Oslo, Oslo, Norway Department of Informatics, University of Oslo, Oslo, Norway.
  • Ozpolat B; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Saatcioglu F; Department of Biosciences, University of Oslo, Oslo, Norway Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway fahris@ibv.uio.no.
EMBO Mol Med ; 7(3): 315-31, 2015 Mar.
Article en En | MEDLINE | ID: mdl-25680860
ABSTRACT
The six transmembrane protein of prostate 2 (STAMP2) is an androgen-regulated gene whose mRNA expression is increased in prostate cancer (PCa). Here, we show that STAMP2 protein expression is increased in human PCa compared with benign prostate that is also correlated with tumor grade and treatment response. We also show that STAMP2 significantly increased reactive oxygen species (ROS) in PCa cells through its iron reductase activity which also depleted NADPH levels. Knockdown of STAMP2 expression in PCa cells inhibited proliferation, colony formation, and anchorage-independent growth, and significantly increased apoptosis. Furthermore, STAMP2 effects were, at least in part, mediated by activating transcription factor 4 (ATF4), whose expression is regulated by ROS. Consistent with in vitro findings, silencing STAMP2 significantly inhibited PCa xenograft growth in mice. Finally, therapeutic silencing of STAMP2 by systemically administered nanoliposomal siRNA profoundly inhibited tumor growth in two established preclinical PCa models in mice. These data suggest that STAMP2 is required for PCa progression and thus may serve as a novel therapeutic target.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oxidorreductasas / Neoplasias de la Próstata / Estrés Oxidativo / Proteínas de la Membrana Tipo de estudio: Prognostic_studies Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2015 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oxidorreductasas / Neoplasias de la Próstata / Estrés Oxidativo / Proteínas de la Membrana Tipo de estudio: Prognostic_studies Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2015 Tipo del documento: Article